Eton Pharmaceuticals (ETON) Equity Average (2018 - 2025)

Eton Pharmaceuticals has disclosed Equity Average across 8 years of filings, most recently posting $24.6 million for Q4 2025.

• Equity Average for Q4 2025 came in at $24.6 million, up 21.95% year-over-year; the trailing twelve-month figure through Dec 2025 was $24.6 million (up 21.95% YoY), and the FY2025 annual result was $25.3 million, up 26.76% from the prior year.
• Equity Average came in at $24.6 million for Q4 2025 at Eton Pharmaceuticals, up from $23.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $24.6 million in Q4 2025 to a low of $12.1 million in Q4 2022.
• The 5-year median for Equity Average is $16.4 million (2021), against an average of $17.5 million.
• Across the five-year window, Equity Average soared 332.31% in 2021 and slumped 37.04% in 2022, its largest moves.
• Eton Pharmaceuticals' Equity Average stood at $16.6 million in 2021, then fell by 27.13% to $12.1 million in 2022, then surged by 33.43% to $16.2 million in 2023, then grew by 24.84% to $20.2 million in 2024, then increased by 21.95% to $24.6 million in 2025.
• The last three Equity Average figures came in at $24.6 million (Q4 2025), $23.5 million (Q3 2025), and $24.2 million (Q2 2025), per Business Quant data.